Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

Metsera said Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer valuing the company for up to $10 billion.

Under Novo Nordisk’s new proposal, the company would pay $62.20 per Metsera common share in cash, as well as certain employee ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as ...

Pfizer raised its full-year profit forecast for the second consecutive quarter and reported a higher-than-expected ...

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk's unsolicited bid to acquire obesity biotech Metsera ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Pfizer reported lower third-quarter profit and sales as demand for its Covid-19 vaccine and antiviral drug continue to decline. The drug maker posted net income of $3.54 billion, or 62 cents a share, ...